Risk of symptomatic radiation necrosis in patients treated with stereotactic radiosurgery for brain metastases

Introduction: Stereotactic radiosurgery (SRS) is a treatment option in the initial management of patients with brain metastases. While its efficacy has been demonstrated in several prior studies, treatment-related complications, particularly symptomatic radiation necrosis (RN), remains as an obstacle for wider implementation of this treatment modality. We thus examined risk factors associated with the development of symptomatic RN in patients treated with SRS for brain metastases. Patients and methods: We performed a retrospective review of our institutional database to identify patients with brain metastases treated with SRS. Diagnosis of symptomatic RN was determined by appearance on serial MRIs, MR spectroscopy, requirement of therapy, and the development of new neurological complaints without evidence of disease progression. Results: We identified 323 brain metastases treated with SRS in 170 patients from 2009 to 2018. Thirteen patients (4%) experienced symptomatic RN after treatment of 23 (7%) lesions. After SRS, the median time to symptomatic RN was 8.3 months. Patients with symptomatic RN had a larger mean target volume (p < 0.0001), and thus larger V100% (p < 0.0001), V50% (p < 0.0001), V12 Gy (p < 0.0001), and V10 Gy (p = 0.0002), compared to the rest of the cohort. Single-fraction treatment (p = 0.0025) and diabetes (p = 0.019) were also significantly associated with symptomatic RN. Conclusion: SRS is an effective treatment option for patients with brain metastases; however, a subset of patients may develop symptomatic RN. We found that patients with larger tumor size, larger plan V100%, V50%, V12 Gy, or V10 Gy, who received single-fraction SRS, or who had diabetes were all at higher risk of symptomatic RN. (C) 2020 Sociedad Espanola de Neurocirugia. Published by Elsevier Espana, S.L.U. All rights reserved.